Medical Case Reports

As Coronavirus is evolving breakthrough infections are not breakthroughs anymore.  The first Israeli who died from Omicron was a fully vaccinated and boosted woman . The first Australian was a fully vaccinated man in his 80s with an underlying health condition. The first US case was a reinfection in an unvaccinated man in his 50s . The first India death  from Omicron was a fully vaccinated 74-year-old man with diabetes. The first Brazilian was a triple-vaccinated 68-year-old man with chronic obstructive pulmonary disease and arterial hypertension. According to  today's technical briefing  from UK Health Security Agency, a total of 57 people has been reported to have died within 28 days of an Omicron COVID-19 diagnosis up to 29 December 2021. The median time from Omicron specimen date to death was 5 days (range 0 to 14). The age of those dying ranged from 41 to 99 years. 23% of Omicron cases were vaccinated with 3 doses, over 50% with two doses, while 25% where not vaccinated at a

A baby whose mother received her second  mRNA-1273  vaccine shot during her last trimester of pregnancy,  1 months and 23 days before his birth,  was born bleeding from his mouth and nose, and died the day after his birth, according to a recent report to the U.S. government’s Vaccine Adverse Event Reporting System from a foreign “regulatory authority.”  The baby boy was born on the morning of October 6, 2021, after his mother received two experimental mRNA Moderna shots on July 19 and August 13. He was expected on October 15 but was delivered weighing 2,800 grams (just over six pounds, two ounces) in hospital after a labor marked by unstable fetal heartbeat. REFERENCE VAERS Report #1879991 See also Baby of ‘fully vaccinated’ mom dies after born bleeding from mouth, nose: VAERS report | marychocomog (wordpress.com) Fully Vaccinated Mother Gives Birth To Baby Bleeding From Nose and Mouth. Newborn Dies Day Later – gospanews.net

I n younger men <40 years the risk of myocarditis was shown to be higher after vaccination than SARS-CoV-2 infection.  Between  December  1,  2020,  to  November  15,  2021  a  total  of  42,200,614  people  were  vaccinated  with  at  least  one  dose  of  ChAdOx1  (n=20,646,456),  BNT162b2  (n=20,391,600)  or  mRNA-1273 (n=1,162,558) in England. Of these, 38,347,981 received  two  doses  of  either  ChAdOx1  (n=20,059,058),  BNT162b2  (n=17,294,004)  or  mRNA-1273  (n=1,039,919) and 10,978,507 people received a third dose of ChAdOx1 (n=35,608), BNT162b2  (n=10,599,183)  or  mRNA-1273  (n=343,716).  Amongst  people  receiving  at  least  one  vaccine  dose, 5,185,772 (12.3%) tested positive for SARS-CoV-2; 2,834,579 (54.7%) prior to vaccination,  698,993 (13.5%) after a first vaccine dose, 1,604,087 (30.9%) after a second vaccine dose and  48,113  (0.9%)  after  a  third  vaccine  dose.  Of  the  42,200,614  persons  included  in  the  study  population, 2,539 (0.006%) were hospita

Among the 54 fully vaccinated patients who developed COVID-19 (data from  ClinicalTrials.gov  study NCT04354701 ) , 35 (65%) were hospitalized, 10 (19%) were admitted to ICU or required MV, and 7 (13%) died within 30 days. Comparable rates were observed in the unvaccinated group. The primary endpoint was 30-day all-cause mortality among fully vaccinated patients compared to the unvaccinated population after Inverse Probability of Treatment Weighting (IPTW) to adjust for baseline clinical variables. SFollowing IPTW, t here was no statistical difference in 30-day mortality between the fully vaccinated patients compared to the unvaccinated cohort Adjusted Odds Ratio (AOR) 1·08, 95% CI: 0·41-2·82. Increased 30-day mortality was associated with lymphopenia (AOR 1·68, 95% CI: 1·11-2·55), the presence of comorbid conditions (mCCI of 1 vs 0: AOR 1·66, 95% CI: 1·07-2·59 and mCCI ≥2 vs 0: AOR 2·10, 95% CI: 1·36-3·24), worse performance status (ECOG PS 1 vs 0: AOR 2·26, 95% CI: 1·25-4·06 or ECOG

  A study from Israel reports 202 deaths among those who were 50 years of age or older at the start of the study and had received two doses of BNT162b2 at least 5 months earlier.  65  of them also received a booster dose.  For participants in the study, sociodemographic data and score for socioeconomic status as well as  diseases such  as diabetes mellitus, chronic obstructive pulmonary disease, asthma, chronic kidney failure, hypertension, ischemic heart disease, chronic heart failure, obesity, lung cancer, or a history of cerebrovascular accident, transient ischemic attack, or smoking was analyzed, but  n o individual-level analysis was provided.  A total of 843,208 participants met the eligibility criteria, of whom 758,118 (90%) received the booster during the 54-day study period. Death due to Covid-19 occurred in 65 participants in the booster group (0.16 per 100,000 persons per day) and in 137 participants in the nonbooster group (2.98 per 100,000 persons per day). The adjusted ha

A study of vaccinated and unvaccinated residents of Bangladesh observed that ChAdOx1 could not prevent the new infection or severe COVID-19 disease outcome with single dose when infections were mostly caused by B.1.351 (the Beta) variants of SARS-CoV2.  About 39% (n = 42) of the respondents were infected after the COVID-19 vaccination. The first dose of ChAdOx1 nCoV-19 vaccine was received by 40 (37.0%) cases and both doses were completed by only 2 (2%) cases. The average duration between vaccination (partially or completely immunized) and  COVID 19  diagnosis was 32 (±17) days.  The hospitalization rate of comorbid patients was 23.5% among the immunized and 24.1% among the nonimmunized groups. There was no significant difference in duration of hospitalization either (p=0.78).  Genomic analysis of SARS-CoV-2 variants of concern identified from the ChAdOx1 nCoV-19 immunized patients from Southwest part of Bangladesh Author links open overlay panel Hassan M. Al-Emran a b 1 Md. Shazid Ha